The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Induction therapy in newly diagnosed multiple myeloma
Enrique Ocio, MD, PhD, of Marqués de Valdecilla University Hospital, Santander, Spain, shares his views on when therapy should be initiated for patients with newly diagnosed multiple myeloma, and gives an overview of how the treatment landscape has changed over time. Dr Ocio discusses different types of induction therapies available and how to allocate therapies to patients who will benefit from earlier treatment, commenting on the potential role of biomarkers. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Enrique M. Ocio, MD, PhD, has received honoraria or consultancy fees from Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD and Mundipharma-EDO.
